6J Biotechnology (Hong Kong) Limited focuses on the development of innovative therapeutics targeting endosomal transport. Its lead candidate, 6J-2, is a first-in-class small molecule designed to inhibit tumor metastasis and is currently advancing toward Phase I clinical trials. The company has been selected for the GASE (GAS) Program at the Hong Kong-Shenzhen Innovation and Technology Park. At the Park, the company aims to advance early-stage clinical development and accelerate the translation and commercialization of its innovative drug candidate.